Skip to main content
Advertisement
Advertisement

TARA

TARA logo

Protara Therapeutics, Inc. Common Stock

3.54
USD
Sponsored
-0.14
-3.80%
Sep 23, 16:00 UTC -4
Closed
exchange

After-Market

3.54

0.00
-0.14%

TARA Earnings Reports

Positive Surprise Ratio

TARA beat 28 of 43 last estimates.

65%

Next Report

Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.37
Implied change from Q2 26 (Revenue/ EPS)
--
/
+2.78%
Implied change from Q3 25 (Revenue/ EPS)
--
/
+19.35%

Protara Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 11, 2026, TARA reported earnings of -0.36 USD per share (EPS) for Q2 26, missing the estimate of -0.33 USD, resulting in a -8.37% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.87% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.37 USD, with revenue projected to reach -- USD, implying an increase of 2.78% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Protara Therapeutics, Inc. Common Stock reported EPS of -$0.36, missing estimates by -8.37%, and revenue of $0.00, 0% as expectations.
The stock price moved down -4.87%, changed from $4.11 before the earnings release to $3.91 the day after.
The next earning report is scheduled for Nov 09, 2026.
Based on 6 analysts, Protara Therapeutics, Inc. Common Stock is expected to report EPS of -$0.37 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement